Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSight™ platform, we are developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect.
Cambridge, United States
Working industry
Other
Type of company
-
Locations
1 Headquarter
Specialised areas
Biotechnology, Health Care, Pharmaceutical
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Exo Therapeutics operates in 1 country around the world
Get an overview of the locations of Exo Therapeutics
Location
Country
State
City
Headquarter
United States
Massachusetts
Cambridge
Some frequent questions that have been asked about Exo Therapeutics
Where is Exo Therapeutics located?
The company headquarter of Exo Therapeutics is located in Cambridge, Massachusetts, United States. It's worth noting, that the company may have more locations
In which industries does Exo Therapeutics mainly work?
The company Exo Therapeutics has it's main focus in the industries of Other
Check out some interesting alternative companies to Exo Therapeutics
EXO Biologics
Niel, Belgium
11-50 Employees
2019
At EXO Biologics, we are united around our belief in the therapeutic potential of Exosomes. Our mission is to provide affordable and accessible therapy to patients with unmet medical needs. We are on a fully integrated site that houses our research, development, and production facilities. We are developing our production platform to load exosomes with therapeutic molecules, such as RNAs, proteins, and chemical drug compounds, for safer and more effective targeted therapies. Founded in Liège in 2019, EXO Biologics works closely with Professor M. At EXO Biologics, we have successfully overcome the challenge of consistent and large-scale production by internally developing a unique production platform. We believe innovation and collaboration are essential to driving progress in exosome therapy. That's why our team comprises highly skilled multidisciplinary scientists dedicated to advancing our understanding and production of exosomes.
Expansion Therapeutics
San Diego, United States
11-50 Employees
2016
We are a team in relentless pursuit of game changing solutions in human health. We believe that the development of small molecule drugs that modulate RNA will dramatically change patient outcomes for diseases where treatment options for patients are currently limited. Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Our team's work is founded upon leading research emerging from Scripps Research.
TargetEx Biosciences Ltd.
Budapest, Hungary
11-50 Employees
2002
TargetEx (formerly known as RecomGenex) was founded in 2002 by an integrated discovery chemistry provider who teamed up with academic researchers with expertise in recombinant technologies. In 2007 TargetEx became an independent company offering complex services in the early phase of drug discovery. TargetEx’ another new business line is the production of various enzymes for kits used in molecular biology and human diagnostics. In 2018 we established an ISO 9001 quality control management system for recombinant protein production, purification and analytics. To provide superior services for biotechnology, health-care and drug discovery.
Exotopic
City of Westminster, United Kingdom
1-10 Employees
2014
Exotopic is growing the Science and Technology sector by investing in the development of new capabilities, services and skills. If your mission requires innovation… involves complexity… is seeking to break new ground… your mission is Exotopic’s mission. You can focus on tackling the subject matter whilst Exotopic clears the path to market.
Kinetic Discovery Ltd.
Dundee, United Kingdom
11-50 Employees
2008
Exscientia AI systems are better at learning than traditional human-led design allowing molecules to reach the clinic faster. Exscientia AI directly challenges this metric by requiring each newly designed molecule to add the maximum information and shorten the path to a clinical molecule. At Exscientia we put AI algorithms at the heart of design and data interpretation. Our mission is to design and develop novel, precision engineered drugs with an improved probability of clinical success for the benefit of patients. We are a creative, passionate and collaborative organisation dedicated to setting bold new standards in drug discovery and design. Finding faster and smarter ways to discover new and better drugs is what drives Exscientia. To address this challenge, we are re-imagining the way drug discovery is implemented, combining the latest AI technique with experimental innovation to engineer a new set of processes for drug discovery.Founded in 2012, we are leading the development of a new discipline; pharmatech, which is at the interface of advanced AI application and complex drug discovery. As a full stack AI drug discovery company, we focus on implementing AI design as well as precision data generation.
neoX Biotech
Beijing, China
11-50 Employees
2018
neoX is a biotech company that combines artificial intelligence (AI) with biophysics for drug research and development. neoX focuses on the research and development of macromolecular drugs and multispecific drugs, especially in the field of immuno-oncology. It has developed a sophisticated platform for early discovery of therapeutics by characterizing protein-protein interactions (PPI). neoX has established cooperation with biomedical companies globally to accelerate drug R&D pipelines.